Prime Medicine, Inc. (PRME) Tops Q3 EPS by 5c

Prime Medicine, Inc. (NASDAQ: PRME) reported Q3 EPS of ($0.44), $0.05 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Prime Medicine, Inc. (PRME) click here.

You May Also Be Interested In

• Dick's Sporting Goods: Analyst sees long-term upside outweighing near-term noise
• Benchmark Reiterates Hold Rating on Texas Roadhouse (TXRH)
• Benchmark Reiterates Hold Rating on Dine Brands (DIN)